Supernus Pharmaceuticals SUPN Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's operating lease liabilities (total)?
- Supernus Pharmaceuticals (SUPN) reported operating lease liabilities (total) of $40.9M in Q1 2026.
- How has Supernus Pharmaceuticals's operating lease liabilities (total) changed year-over-year?
- Supernus Pharmaceuticals's operating lease liabilities (total) increased by 26.6% year-over-year, from $32.31M to $40.9M.
- What is the long-term trend for Supernus Pharmaceuticals's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's operating lease liabilities (total) has grown at a 4.8% compound annual growth rate (CAGR), from $32.34M to $40.98M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.